Chiara Fallerini

Dr. Chiara Fallerini

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2020 in Cell
Verified
Journal Article
Closed access
FSF. Kyle Satterstrom
F. Kyle Satterstrom
JKJack A. Kosmicki
Jack A. Kosmicki
JWJiebiao Wang
Jiebiao Wang
MBMichael S. Breen
Michael S. Breen
SRSilvia De Rubeis
Silvia De Rubeis
JBJoseph D. Buxbaum
Joseph D. Buxbaum

2 March 2021 in eLife
Verified
Journal Article
Open access
CFChiara Fallerini
Chiara Fallerini
SDSergio Daga
Sergio Daga
SMStefania Mantovani
Stefania Mantovani
EBElisa Benetti
Elisa Benetti
NPnicola picchiotti
nicola picchiotti
EFElisa Frullanti
Elisa Frullanti
Background: Recently, loss-of-function variants in TLR7 were identified in two families in which COVID-19 segregates like an X-linked recessive disorder environmentally conditioned by SARS-CoV-2. We investigated whether the two families represent the tip of the iceberg of a subset of COVID-19 male patients.Methods: This is a nested case-control study in which we compared male participants with extreme phenotype selected from the Italian GEN-COVID cohort of SARS-CoV-2-infected participants (<60 y, 79 severe cases versus 77 control cases). We applied the LASSO Logistic Regression analysis, considering only rare variants on young male subsets with extreme phenotype, picking up TLR7 as the most important susceptibility gene.Results: Overall, we found TLR7 deleterious variants in 2.1% of severely affected males and in none of the asymptomatic participants. The functional gene expression profile analysis demonstrated a reduction in TLR7-related gene expression in patients compared with controls demonstrating an impairment in type I and II IFN responses.Conclusions: Young males with TLR7 loss-of-function variants and severe COVID-19 represent a subset of male patients contributing to disease susceptibility in up to 2% of severe COVID-19.Funding: Funded by private donors for the Host Genetics Research Project, the Intesa San Paolo for 2020 charity fund, and the Host Genetics Initiative.Clinical trial number: NCT04549831.

9 January 2015 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
MMMaria Antonietta Mencarelli
Maria Antonietta Mencarelli
LHLaurence Heidet
Laurence Heidet
HSHelen Storey
Helen Storey
MGMichel van Geel
Michel van Geel
BKBertrand Knebelmann
Bertrand Knebelmann
ARAlessandra Renieri
Alessandra Renieri
Background Alport syndrome is a clinically heterogeneous, progressive nephropathy caused by mutations in collagen IV genes, namely COL4A3 and COL4A4 on chromosome 2 and COL4A5 on chromosome X. The wide phenotypic variability and the presence of incomplete penetrance suggest that a simple Mendelian model cannot completely explain the genetic control of this disease. Therefore, we explored the possibility that Alport syndrome is under digenic control. Methods Using massively parallel sequencing, we identified 11 patients who had pathogenic mutations in two collagen IV genes. For each proband, we ascertained the presence of the same mutations in up to 12 members of the extended family for a total of 56 persons studied. Results Overall, 23 mutations were found. Individuals with two pathogenic mutations in different genes had a mean age of renal function deterioration intermediate with respect to the autosomal-dominant form and the autosomal-recessive one, in line with molecule stoichiometry of the disruption of the type IV collagen triple helix. Conclusions Segregation analysis indicated three possible digenic segregation models: (i) autosomal inheritance with mutations on different chromosomes, resembling recessive inheritance (five families); (ii) autosomal inheritance with mutations on the same chromosome resembling dominant inheritance (two families) and (iii) unlinked autosomal and X-linked inheritance having a peculiar segregation (four families). This pedigree analysis provides evidence for digenic inheritance of Alport syndrome. Clinical geneticists and nephrologists should be aware of this possibility in order to more accurately assess inheritance probabilities, predict prognosis and identify other family members at risk.

4 September 2013 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
CFChiara Fallerini
Chiara Fallerini
LDL. Dosa
L. Dosa
RTR. Tita
R. Tita
DPD. Del Prete
D. Del Prete
SFS. Feriozzi
S. Feriozzi
Francesca ArianiFrancesca Ariani
Francesca Ariani

24 December 2021 in Genes & Immunity
Verified
Journal Article
Open access
PDF file
SMStefania Mantovani
Stefania Mantovani
SDSergio Daga
Sergio Daga
CFChiara Fallerini
Chiara Fallerini
MBMargherita Baldassarri
Margherita Baldassarri
EBElisa Benetti
Elisa Benetti
ARAlessandra Renieri
Alessandra Renieri
Toll-like receptors (TLR) are crucial components in the initiation of innate immune responses to a variety of pathogens, triggering the production of pro-inflammatory cytokines and type I and II interferons, which are responsible for innate antiviral responses. Among the different TLRs, TLR7 recognizes several single-stranded RNA viruses including SARS-CoV-2. We and others identified rare loss-of-function variants in X-chromosomal TLR7 in young men with severe COVID-19 and with no prior history of major chronic diseases, that were associated with impaired TLR7 signaling as well as type I and II IFN responses. Here, we performed RNA sequencing to investigate transcriptome variations following imiquimod stimulation of peripheral blood mononuclear cells isolated from patients carrying previously identified hypomorphic, hypofunctional, and loss-of-function TLR7 variants. Our investigation revealed a profound impairment of the TLR7 pathway in patients carrying loss-of-function variants. Of note, a failure in IFNγ upregulation following stimulation was also observed in cells harboring the hypofunctional and hypomorphic variants. We also identified new TLR7 variants in severely affected male patients for which a functional characterization of the TLR7 pathway was performed demonstrating a decrease in mRNA levels in the IFNα, IFNγ, RSAD2, ACOD1, IFIT2, and CXCL10 genes.

Verified
Journal Article
Open access
PDF file
LBLucia Bruno
Lucia Bruno
GDGabriella Doddato
Gabriella Doddato
FVFloriana Valentino
Floriana Valentino
MBMargherita Baldassarri
Margherita Baldassarri
RTRossella Tita
Rossella Tita
Francesca ArianiFrancesca Ariani
Francesca Ariani
Intellectual disability (ID) is characterized by impairments in the cognitive processes and in the tasks of daily life. It encompasses a clinically and genetically heterogeneous group of neurodevelopmental disorders often associated with autism spectrum disorder (ASD). Social and communication abilities are strongly compromised in ASD. The prevalence of ID/ASD is 1–3%, and approximately 30% of the patients remain without a molecular diagnosis. Considering the extreme genetic locus heterogeneity, next-generation sequencing approaches have provided powerful tools for candidate gene identification. Molecular diagnosis is crucial to improve outcome, prevent complications, and hopefully start a therapeutic approach. Here, we performed parent–offspring trio whole-exome sequencing (WES) in a cohort of 60 mostly syndromic ID/ASD patients and we detected 8 pathogenic variants in genes already known to be associated with ID/ASD (SYNGAP1, SMAD6, PACS1, SHANK3, KMT2A, KCNQ2, ACTB, and POGZ). We found four de novo disruptive variants of four novel candidate ASD/ID genes: MBP, PCDHA1, PCDH15, PDPR. We additionally selected via bioinformatic tools many variants in unknown genes that alone or in combination can contribute to the phenotype. In conclusion, our data confirm the efficacy of WES in detecting pathogenic variants of known and novel ID/ASD genes.